Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization11The names and institutions participating in these trials are provided in the appendices of references 1 to 3.
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference26 articles.
1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty;N Engl J Med,1994
2. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization;N Engl J Med,1997
3. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade;Lancet,1998
4. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention;Lancet,1997
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty;Circulation,1997
Cited by 111 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Endovascular drug-delivery and drug-elution systems;Biomechanics of Coronary Atherosclerotic Plaque;2021
2. Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis;Nature Communications;2020-01-21
3. A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies;Evidence-Based Complementary and Alternative Medicine;2019-01-03
4. Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series;Cardiovascular Revascularization Medicine;2018-01
5. Safety and Effectiveness of Adjunctive Intra-Arterial Abciximab in the Management of Acute Limb Ischemia;Annals of Vascular Surgery;2016-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3